Literature DB >> 15862958

Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.

J S Lewis1, C Osipo, K Meeke, V C Jordan.   

Abstract

Estrogen suppression through the use of an aromatase inhibitor is an effective endocrine treatment option for postmenopausal breast cancer patients with estrogen receptor (ER)-positive disease, however, there are concerns that long-term estrogen deprivation will inevitably lead to resistance. To address the issue of acquired resistance to long-term estrogen deprivation our laboratory has developed an ER+/PR- hormone-independent breast cancer cell line, MCF-7:5C which is a variant clone of wild-type MCF-7 cells. Originally, these cells were cultured in estrogen-free MEM containing 5% charcoal-stripped calf serum and were found to be resistant to both estradiol (E(2)) and antiestrogens. Interestingly, a completely different phenomenon was observed when MCF-7:5C cells were cultured in phenol red-free RPMI 1640 medium containing 10% charcoal-stripped fetal bovine serum (SFS). Using DNA quantitation assays, we examined the effect of E(2) on the growth of MCF-7:5C cells under different media conditions. Our results showed that 10(-9)M E(2) caused a dramatic 90% reduction in the growth of MCF-7:5C cells cultured in RPMI medium containing 10% SFS but did not have any significant inhibitory effects on cells cultured in MEM media. Additional experiments were performed to determine whether the medium or the serum facilitated the inhibitory effects of E(2) and the results indicated that it was the serum. Annexin V and DAPI staining confirmed that the E(2)-induced growth inhibition of MCF-7:5C cells was due to apoptosis. We also examined the tumorigenic potential of MCF-7:5C cells by injecting 1x10(7)cells/site into ovariectomized athymic mice and found that these cells, previously cultured in RPMI media, spontaneously grew into tumors in the absence of E(2). Overall, these results show that low concentrations (>10(-11)M) of E(2) are capable of inducing apoptosis in an aromatase resistant breast cancer cell model and that this effect is highly influenced by the medium in which the cells are grown.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862958     DOI: 10.1016/j.jsbmb.2004.12.032

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  53 in total

1.  NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis.

Authors:  Y S Lobanova; A M Scherbakov; V A Shatskaya; V A Evteev; M A Krasil'nikov
Journal:  Mol Cell Biochem       Date:  2008-12-20       Impact factor: 3.396

2.  Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.

Authors:  Joan S Lewis-Wambi; Ramona Swaby; Helen Kim; V Craig Jordan
Journal:  J Steroid Biochem Mol Biol       Date:  2009-01-09       Impact factor: 4.292

3.  The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Authors:  V Craig Jordan; Ifeyinwa Obiorah; Ping Fan; Helen R Kim; Eric Ariazi; Heather Cunliffe; Hiltrud Brauch
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

4.  Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.

Authors:  Eric A Ariazi; Heather E Cunliffe; Joan S Lewis-Wambi; Michael J Slifker; Amanda L Willis; Pilar Ramos; Coya Tapia; Helen R Kim; Smitha Yerrum; Catherine G N Sharma; Emmanuelle Nicolas; Yoganand Balagurunathan; Eric A Ross; V Craig Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-19       Impact factor: 11.205

5.  Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells.

Authors:  Xin-Tian Zhang; Ling Ding; Lian-Guo Kang; Zhao-Yi Wang
Journal:  Oncol Rep       Date:  2012-03-15       Impact factor: 3.906

6.  The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

Authors:  Joan S Lewis-Wambi; Helen Kim; Ramona Curpan; Ronald Grigg; Mohammed A Sarker; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2011-07-07       Impact factor: 4.436

Review 7.  Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Authors:  V Craig Jordan; Joan Lewis-Wambi; Helen Kim; Heather Cunliffe; Eric Ariazi; Catherine G N Sharma; Heather A Shupp; Ramona Swaby
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

8.  Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

Authors:  I E Obiorah; V C Jordan
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

9.  Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.

Authors:  Ping Fan; V Craig Jordan
Journal:  Steroids       Date:  2014-06-12       Impact factor: 2.668

Review 10.  Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

Authors:  Joan S Lewis-Wambi; V Craig Jordan
Journal:  Breast Cancer Res       Date:  2009-05-29       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.